Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 17, 2013. The report details a corporate action regarding the cancellation of treasury shares authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital structure and treasury holdings.
Material Changes
- Share Cancellation: On December 17, 2013, the company cancelled 30,000,000 shares of 25 pence each held as Treasury shares.
- Treasury Holdings: Following the cancellation, the company holds 486,618,909 shares in Treasury, representing 9.11% of total issued share capital.
- Voting Rights: Including shares purchased but not yet settled, the company holds 487,433,663 shares in Treasury, representing 10.04% of current total voting rights.
- Shares in Issue: The company has 4,855,309,556 shares in issue (excluding Treasury shares), which represents the total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the updated total issued share capital of 4,855,309,556 shares for calculating ownership thresholds.
- Confirm the reduction in Treasury shares to 486,618,909 (9.11% of issued capital) following the December 17 cancellation.
- Note that 10.04% of total voting rights are currently held in Treasury when including unsettled purchases.